Plasmalogens are membrane phospholipids whose vinyl-ether bond makes them sacrificial antioxidants; they concentrate in brain and heart and fall steeply after age 50. Low blood levels robustly predict cognitive decline in cohort data including Framingham. The intervention evidence is much thinner: one open-label trial of a DHA precursor (n=22) raised blood plasmalogens dose-dependently and 41% of participants improved on the CDR scale, but there is no placebo-controlled trial, and the FDA warned the lead researcher's clinic in 2025 for studying supplements without an IND.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Do plasmalogen supplements work?
Unproven. The one published trial (open-label, n=22, cognitively impaired) showed dose-dependent restoration of blood plasmalogens, better oxidative-stress biomarkers, and 41% of participants improving on the CDR scale, but 41% were unchanged and 18% declined. No placebo-controlled trial exists.11
Do plasmalogen levels really decline with age?
This part is solid. Levels peak around 30 to 40, fall steeply after 50, and sit about 40% lower by 70-plus. Low blood DHA-plasmalogen predicted future cognitive decline in the Framingham cohort (n>1,800), and Alzheimer's brains show 30-40% reduced DHA-plasmalogens.
Is plasmalogen supplementation safe?
Short-term safety looked fine: the open-label trial reported no adverse reactions, and a first-in-human study of the synthetic precursor PPI-1011 confirmed safety and tolerability. There is no long-term safety data beyond one year.13
Why the controversy around plasmalogens?
The clinical program is dominated by one researcher who sells both the supplements and the blood test, and in January 2025 the FDA warned his clinic for conducting a supplement study without a required IND application, questioning the data's validity. The underlying deficiency science is independent and sound.
What would change this rating?
An independent, placebo-controlled, IND-governed trial of plasmalogen precursors in cognitive impairment, plus long-term safety data and replication outside the founder's group.
Core thesis: Plasmalogens are a specialized class of phospholipids with a unique vinyl-ether bond at the sn-1 position, enriched in brain, heart, and immune cell membranes. They function as endogenous antioxidants, membrane structure modulators, and signaling molecule precursors. Blood and brain plasmalogen levels decline precipitously with age — particularly after age 50 — and this decline is strongly associated with cognitive decline, neurodegenerative disease (especially Alzheimer's and Parkinson's), sarcopenia, and cardiovascular disease. Targeted plasmalogen supplementation with DHA-enriched precursors has shown dose-dependent restoration of blood plasmalogen levels, improvement in oxidative stress biomarkers, and preliminary cognitive/mobility benefits in clinical trials.
02Biochemistry of Plasmalogens
Structure
Plasmalogens are a subclass of glycerophospholipids distinguished by a vinyl-ether bond at the sn-1 position of the glycerol backbone (vs. the ester bond in conventional phospholipids).
| Feature | Plasmalogens (Pls) | Phosphatidyl-Lipids (Ptd) |
|---|---|---|
| sn-1 bond | Vinyl-ether (alk-1-enyl) | Ester (acyl) |
| sn-2 fatty acid | Typically DHA or AA (PUFA) | Variable |
| sn-3 head group | Ethanolamine (PlsEtn) or Choline (PlsCho) | Ethanolamine or Choline |
| Key property | Vinyl-ether bond is a sacrificial antioxidant target | Standard membrane lipid |
Swipe table →
Types
- Ethanolamine plasmalogens (PlsEtn): ~80% of total plasmalogens; enriched in brain, heart, skeletal muscle. The predominant form relevant to neurodegeneration.
- Choline plasmalogens (PlsCho): ~20%; enriched in heart and lung surfactant.
Biosynthesis
Plasmalogen synthesis occurs in peroxisomes (initial steps) and endoplasmic reticulum (completion):
- Dihydroxyacetone phosphate (DHAP) + acyl-CoA → acyl-DHAP (peroxisomal acyltransferase)
- Alkyl-DHAP synthase replaces the acyl group with a fatty alcohol → alkyl-DHAP (peroxisome)
- Import to ER; further modifications: reduction, acylation at sn-2, desaturation to create vinyl-ether bond
- Final products: PlsEtn with DHA at sn-2 (the predominant brain species)
Clinical significance: Peroxisomal disorders (e.g., Zellweger syndrome) cause severe plasmalogen deficiency, confirming the peroxisomal dependence and the critical role of plasmalogens in neural development.
Tissue Distribution
| Tissue | Plasmalogen Content | Notes |
|---|---|---|
| Brain | Very high (up to 30% of ethanolamine phospholipids) | Myelin sheaths, synaptic membranes |
| Heart | High | Mitochondrial membranes,导电 cells |
| Skeletal muscle | Moderate | Mitochondrial function |
| Immune cells | Moderate | Macrophage/lymphocyte membranes |
| Erythrocytes | Moderate | Easily measured as blood biomarker |
Swipe table →
03Functions of Plasmalogens
1. Endogenous Antioxidant (Primary)
The vinyl-ether bond is uniquely susceptible to oxidation by reactive oxygen species (ROS). This makes plasmalogens sacrificial scavengers:
- Plasmalogen vinyl-ether bond + ROS → oxidized plasmalogen (inert) + H₂O
- This reaction protects adjacent polyunsaturated fatty acids (DHA, AA) from peroxidation
- Plasmalogens are the first line of defense against membrane lipid peroxidation
- Without sufficient plasmalogens, DHA and AA in membranes undergo uncontrolled oxidative damage
Evidence: Sindelar et al. (1999) demonstrated that plasmalogen vinyl-ether bonds react with ROS at rates 10-100× faster than PUFAs, confirming their sacrificial antioxidant role.
2. Membrane Structure and Fluidity
- Plasmalogens have a smaller head group than phosphatidyl lipids, creating tighter packing in the membrane
- This affects membrane fluidity, curvature, and fusion capacity
- Critical for vesicle formation and neurotransmitter release in neurons
- Essential for myelin sheath integrity and conduction velocity
3. Cholesterol Metabolism Regulation
Plasmalogens modulate HDL-mediated cholesterol transport: - DHA-plasmalogens dose-dependently increase cholesterol esterification via acyl-CoA acetyltransferase (ACAT) - They reduce free cholesterol in membranes - This may explain the association between low plasmalogens and atherosclerosis
4. Amyloid Pathway Modulation
- Increasing membrane DHA-plasmalogen levels upregulates alpha-secretase (non-amyloidogenic APP processing)
- Results in decreased Aβ 1-42 production (the toxic amyloid species)
- DHA-plasmalogen precursor blocks the increase in Aβ 1-42 caused by cholesterol loading (Wood et al., 2011)
5. Neurotransmission and Synaptic Function
- Plasmalogens are enriched in synaptic vesicle membranes
- Required for efficient vesicle fusion and neurotransmitter release
- Low plasmalogens impair cholinergic neurotransmission (relevant to Alzheimer's)
- Oral plasmalogen supplementation in mice increased hippocampal BDNF expression (Hossain et al., 2022)
6. Immune Function
- Plasmalogens are precursors to platelet-activating factor (PAF) and eicosanoids
- Macrophage plasmalogen content influences phagocytosis efficiency
- Low plasmalogens associated with chronic inflammatory states
04Plasmalogen Decline in Aging and Disease
Age-Related Decline
Plasmalogen levels follow a predictable lifecycle pattern:
| Age Range | Plasmalogen Level | Significance |
|---|---|---|
| 0-30 | Increasing to peak | Brain development, maturation |
| 30-40 | Plateau / slow decline | Optimal levels |
| 40-50 | Decline begins | Subclinical |
| 50-70 | Steep decline | Cognitive vulnerability increases |
| 70+ | Severely depleted | ~40% reduction from peak (Rouser & Yamamoto, 1968) |
Swipe table →
This decline is driven by: - Decreased peroxisomal function with age - Increased oxidative stress consuming plasmalogens as sacrificial antioxidants - Reduced biosynthetic enzyme activity - Cumulative free radical damage to existing plasmalogen pool
Association with Neurodegenerative Disease
The association between low plasmalogens and cognitive decline is described as "robust and reproducible" across dozens of studies:
| Disease | Plasmalogen Finding | Key Reference |
|---|---|---|
| Alzheimer's disease | 30-40% reduction in brain DHA-plasmalogens | Goodenowe et al. 2007 (Framingham Study, n=1,800+) |
| Parkinson's disease | Reduced plasmalogens in substantia nigra | Goodenowe 2021; Wu et al. 2024 (nasal plasmalogen nano-medicine) |
| Multiple sclerosis | Decreased myelin plasmalogens | Dorninger et al. 2017 |
| Age-related cognitive decline | Blood DHA-plasmalogen levels predict cognitive function | Kling et al. 2020; Lim et al. 2020 |
Swipe table →
Framingham Heart Study: Goodenowe et al. analyzed plasmalogen levels in blood from the Framingham cohort (n>1,800). Low blood DHA-plasmalogen levels were predictive of future cognitive decline — even decades before symptom onset. This is among the strongest epidemiological evidence for plasmalogens as a biomarker.
Association with Sarcopenia and Mobility
- Reduced blood DHA-plasmalogen levels correlate with decreased grip strength and slower gait speed
- Plasmalogen-deficient mice show neuromuscular junction defects (Dorninger et al. 2017)
- Sarcopenia prevalence is ~3× higher in persons with dementia vs. without (Pacifico et al. 2020), suggesting shared plasmalogen-dependent mechanism
05Doses in studies
Goodenowe et al. 2022 (Frontiers in Cell and Developmental Biology)
Citation: Goodenowe DB, Haroon J, Kling MA, et al. "Targeted plasmalogen supplementation: Effects on blood plasmalogens, oxidative stress biomarkers, cognition, and mobility in cognitively impaired persons." Front Cell Dev Biol. 2022;10:864842. doi:10.3389/fcell.2022.864842. PMID: 35874835. NCT: NCT04484454
Study Design
- Participants: 22 cognitively impaired persons (CDR 0.5-3), ages 37-84 (mean 67)
- Intervention: Oral DHA-AAG (1-O-alkyl-2-acylglycerol with DHA at sn-2), a synthetic plasmalogen precursor
- Dosing schedule (escalating):
- Product: ProdromeSciences DHA-AAG; C16:C18 alkylglycerol backbone (chimyl/batyl alcohol), >95% DHA at sn-2/sn-3, algae-derived, purity >98%
Key Results
Pharmacokinetics (Blood DHA-Plasmalogen Levels): - DHA-plasmalogen levels increased dose-dependently - Significant elevation at all doses and time points (p<0.05 vs. baseline) - Direct target (DHA-PL) increased more than indirect targets (DHA-PE, LA/AA-PL) - No effect on biochemically unrelated species ((LA+AA)-PE) — confirming specificity - Levels declined during washout month but remained above baseline
Oxidative Stress Biomarkers:
| Biomarker | Effect | Significance |
|---|---|---|
| Malondialdehyde (MDA) | ↓ Decreased | Lipid peroxidation reduced (correlated with DHA-PL levels) |
| Catalase (CAT) | ↑ Increased | Hydrogen peroxide neutralization improved |
| Superoxide dismutase (SOD) | Normalized | Reduced in those with high baseline SOD |
Swipe table →
- DHA-PL levels were positively associated with catalase activity (p=0.0022)
- DHA-PL levels were negatively associated with MDA (p=0.033)
- Plasmalogens normalized oxidant/antioxidant balance in both directions
Cognitive Outcomes (CDR scale):
| Outcome | Participants | Percentage |
|---|---|---|
| Improved (≥1 CDR unit change) | 9/22 | 41% |
| Unchanged | 9/22 | 41% |
| Declined | 4/22 | 18% |
Swipe table →
Mobility Outcomes (30-sec Sit/Stand):
| Outcome | Participants | Percentage |
|---|---|---|
| Improved (≥2 repetitions) | 12/22 | 55% |
| Unchanged | 5/22 | 23% |
| Declined | 4/22 | 18% |
Swipe table →
Critical Assessment: - No placebo group — this was an open-label investigational trial - 41% improvement rate is meaningful but 41% unchanged and 18% declined - Baseline DHA-plasmalogen levels were not predictive of clinical response - Cognition improvement was statistically significant vs. random outcome probability - Authors note product was well tolerated with no adverse reactions
Other Clinical Studies
| Study | Design | Key Finding | Citation |
|---|---|---|---|
| Fujino et al. 2017 | RCT, healthy adults, plasmalogen supplement | Improved cognition and mood; 2g/day dose | J Oleo Sci |
| Fujino et al. 2018 | Follow-up study | Confirmed cognitive benefit in older adults | J Oleo Sci |
| Watanabe 2020 | RCT (Nihon Pharmaceutical) | Plasmalogen vs. Prevagen comparison; plasmalogen group showed cognitive benefit | J Oleo Sci |
| Smith et al. 2025 | First-in-human PK study (PPI-1011) | Safety, tolerability confirmed for synthetic precursor | Clin Transl Sci. doi:10.1111/cts.70195 |
Swipe table →
Animal Model Evidence
- Plasmalogen-deficient mice: Neuromuscular junction defects, cognitive impairment, reduced lifespan (Dorninger et al. 2017)
- Parkinson's model: Intranasal plasmalogen nanomedicine improved dopaminergic neuron survival (Wu et al. 2024, Adv Healthc Mater)
- Alzheimer's model: DHA-AAG reduced Aβ 1-42 and improved memory in APP-transgenic mice (Wood et al. 2011)
- Cardiac dysfunction: Alkylglycerol supplementation restored cardiac plasmalogens and mitochondrial function in dilated cardiomyopathy mice (2025 study)
- C. elegans lifespan: Plasmalogen supplementation extended lifespan (suggesting geroprotective potential)
06Doses in studies
Commercial Products
| Product | Manufacturer | Form | Composition | Cost Range |
|---|---|---|---|---|
| ProdromeGlia | Prodrome Sciences (Goodenowe) | Oral liquid | DHA-AAG plasmalogen precursor | ~$150-200/month |
| ProdromeBrain | Prodrome Sciences | Oral liquid | DHA-AAG (higher dose) | ~$200-300/month |
| Daiwa Brain Health | Daiwa | Capsules | 0.5 mg plasmalogen/capsule | ~$50-80/month |
| Nihon Seiken | Nihon Pharmaceutical | Capsules | Purified plasmalogens (ascidian source) | Japan market |
| Alkylglycerol (shark liver oil) | Various | Oil/softgel | Natural alkylglycerols (precursors) | ~$20-40/month |
Swipe table →
⚠️ Quality concern: Products vary enormously in bioactive plasmalogen/precursor content. The Goodenowe DHA-AAG formulation is the most clinically validated but also the most expensive and associated with regulatory controversy (see below).
Blood Testing
- ProdromeScan (Prodrome Sciences): Blood test measuring ethanolamine plasmalogen species (DHA-PL, AA-PL) vs. phosphatidyl species
- Report: Provides DHA-PL/(LA+AA)-PE ratio — the key aging/disease biomarker
- Cost: ~$200-300
- Clinical availability: Direct-to-consumer; not standard lab test
07Regulatory and Ethical Concerns
FDA Warning (January 2025)
The FDA issued a warning letter to Goodenowe's clinic stating that a supplement study failed to file the required Investigational New Drug (IND) application. The FDA wrote that this failure: - "Raises significant concerns about the safety and welfare of enrolled subjects" - "Raises concerns about the validity and integrity of the data collected"
Assessment: Plasmalogen biochemistry and deficiency associations are legitimate and well-established. Goodenowe's original scientific work identifying the deficiency is sound. However, the clinical program has been marred by regulatory non-compliance and commercial conflicts of interest. The preclinical data for Parkinson's and age-related cognitive decline is promising but requires independent replication through proper IND-governed trials.
Key Concerns
- Founder bias: Goodenowe founded Prodrome Sciences (sells supplements and tests) — inherent conflict of interest
- No independent RCTs: The main clinical evidence comes from Goodenowe-affiliated researchers
- Open-label designs: No placebo-controlled trials published to date
- Cost barriers: Products are expensive ($150-300/month for clinical doses)
- Safety profile: Short-term safety appears good, but no long-term (>1 year) safety data exists
08Evidence Quality Summary
| Evidence Type | Status | Rating |
|---|---|---|
| Plasmalogen decline in aging (epidemiological) | Multiple cohorts, Framingham data | Strong |
| Association with cognitive decline | Robust, reproducible across labs | Strong |
| Mechanism (antioxidant, membrane) | In-vitro and animal data solid | Strong |
| Supplementation PK (blood levels) | One open-label trial, dose-dependent | Moderate |
| Cognitive benefit of supplementation | Open-label, 41% improved | Preliminary |
| Independent RCTs | None published | Absent |
| Long-term safety | No data | Unknown |
Swipe table →
09Connections
10Sources
- Goodenowe DB, Haroon J, Kling MA, et al. Targeted plasmalogen supplementation: effects on blood plasmalogens, oxidative stress biomarkers, cognition, and mobility in cognitively impaired persons. Front Cell Dev Biol . 2022;10:864842. PMID: 35874835 . doi: 10.3389/fcell.2022.864842DOI 10.3389/fcell.2022.864842 · PubMed 35874835
- NCT04484454NCT04484454
- Smith T, Knudsen KJ, Ritchie SA. (2025). First-in-human safety, tolerability, and pharmacokinetics of PPI-1011, a synthetic plasmalogen precursor. Clin Transl Sci . 18. doi: 10.1111/cts.70195DOI 10.1111/cts.70195
- Dorninger F, et al. (2017). Plasmalogen deficiency in mice causes neuromuscular junction defects. Dorninger et al. PMID: 28108285PubMed 28108285
- Wu Y, et al. (2024). Lipid and transcriptional regulation in a Parkinson's disease mouse model by intranasal plasmalogen nanomedicines. Adv Healthc Mater . 13:2304588. doi: 10.1002/adhm.202304588DOI 10.1002/adhm.202304588
- Sindelar PJ, et al. (1999). Plasmalogens and oxidative stress: the vinyl ether bond as a sacrificial antioxidant target. Sindelar et al. PMID: 10456357PubMed 10456357
11Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.